Ethicon Acquires Rights of Takeda’s TachoSil Fibrin Sealant Patch for ~$400M

 Ethicon Acquires Rights of Takeda’s TachoSil Fibrin Sealant Patch for ~$400M

Ethicon Acquires Rights of Takeda’s TachoSil Fibrin Sealant Patch for ~$400M

Shots:

  • Takeda tosells its TachoSil Fibrin Sealant Patch along with its ~80 employees to Ethicon for ~ 400M. The transaction is expected to close in H2’19
  • Ethicon to acquire the assets and licenses that support the manufacturing, licensing and commercialization of TachoSil while Takeda will retain rights to TachoSil products and supply it to Ethicon
  • TachoSil, Fibrin Sealant Patch is a surgical patch designed to control bleeding and generated a revenue of $155M in 2018

Click here to read full press release/ article | Ref: Takeda | Image: Insider

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post